LINC01254: A Potential Drug Target and Biomarker (G101927350)

Target Name: LINC01254

NCBI ID: G101927350

LINC01254

Other Name(s): Long intergenic non-protein coding RNA 1254 | long intergenic non-protein coding RNA 1254

LINC01254: A Potential Drug Target and Biomarker

LINC01254 is a non-protein coding RNA (ncRNA) molecule that has been identified as a potential drug target and biomarker. It is located within the intron of the gene PMZ223317, which encodes a protein known as PMZ223318. PMZ223318 is a protein that is involved in the intracellular signaling pathway known as the NF-kappa pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases, including cancer.

The NF-kappa pathway is a complex signaling pathway that is involved in the regulation of many cellular processes, including cell growth, differentiation, and survival. It is a key factor in the development and progression of many diseases, including cancer, and is a potential drug target for the development of new therapies.

LINC01254 is a non-protein coding RNA molecule that is located within the intron of the gene PMZ223317, which encodes a protein known as PMZ223318. PMZ223318 is a protein that is involved in the intracellular signaling pathway known as the NF-kappa pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases, including cancer.

The NF-kappa pathway is a complex signaling pathway that is involved in the regulation of many cellular processes, including cell growth, differentiation, and survival. It is a key factor in the development and progression of many diseases, including cancer, and is a potential drug target for the development of new therapies.

LINC01254 is a potential drug target because it is involved in the regulation of the NF-kappa pathway. This pathway is a key factor in the development and progression of many diseases, including cancer, and targeting LINC01254 could potentially lead to the development of new therapies that can treat these diseases.

LINC01254 is also a potential biomarker for the diagnosis and prognosis of many diseases, including cancer. The NF-kappa pathway is involved in the regulation of many cellular processes, including cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases. By targeting LINC01254, researchers could potentially develop new diagnostic tests and biomarkers for the diagnosis and prognosis of these diseases.

The Identification of LINC01254 as a Potential Drug Target

The identification of LINC01254 as a potential drug target was based on its location within the intron of the gene PMZ223317, which encodes a protein known as PMZ223318. PMZ223318 is a protein that is involved in the intracellular signaling pathway known as the NF-kappa pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases, including cancer.

LINC01254 is a non-protein coding RNA molecule that is expressed in many different tissues and cells. It is located within the intron of the gene PMZ223317, which encodes a protein known as PMZ223318. PMZ223318 is a protein that is involved in the intracellular signaling pathway known as the NF-kappa pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases, including cancer.

The identification of LINC01254 as a potential drug target was based on its location within the intron of the gene PMZ223317, which encodes a protein known as PMZ223318. PMZ223318 is a protein that is involved in the intracellular signaling pathway known as the TGF-

Protein Name: Long Intergenic Non-protein Coding RNA 1254

The "LINC01254 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01254 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets